4.6 Review

Overcoming the Prokaryote/Eukaryote Barrier in Tuberculosis Treatment: A Prospect for the Repurposing and Use of Antiparasitic Drugs

期刊

MICROORGANISMS
卷 9, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/microorganisms9112335

关键词

antituberculosis drugs; antiparasitic drugs; drug resistance; repurposing; drug discovery

资金

  1. Spanish Ministry of University (Programa de Formacion de Profesorado Universitario) [FPU18/03873]
  2. Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior-Brazil (CAPES) [001]

向作者/读者索取更多资源

Antimicrobial resistance poses a significant challenge, pushing the need for novel drugs with new mechanisms of action. Drug repurposing has emerged as a fast, cost-effective, and efficient strategy in developing new antimicrobial agents for tuberculosis treatment.
Antimicrobial resistance, the so-called silent pandemic, is pushing industry and academia to find novel antimicrobial agents with new mechanisms of action in order to be active against susceptible and drug-resistant microorganisms. In the case of tuberculosis, the need of novel anti-tuberculosis drugs is specially challenging because of the intricate biology of its causative agent, Mycobacterium tuberculosis. The repurposing of medicines has arisen in recent years as a fast, low-cost, and efficient strategy to identify novel biomedical applications for already approved drugs. This review is focused on anti-parasitic drugs that have additionally demonstrated certain levels of anti-tuberculosis activity; along with this, natural products with a dual activity against parasites and against M. tuberculosis are discussed. A few clinical trials have tested antiparasitic drugs in tuberculosis patients, and have revealed effective dose and toxicity issues, which is consistent with the natural differences between tuberculosis and parasitic infections. However, through medicinal chemistry approaches, derivatives of drugs with anti-parasitic activity have become successful drugs for use in tuberculosis therapy. In summary, even when the repurposing of anti-parasitic drugs for tuberculosis treatment does not seem to be an easy job, it deserves attention as a potential contributor to fuel the anti-tuberculosis drug pipeline.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据